autologous MAGE-C2-specific HLA-A2-restricted TCR T lymphocytes

A preparation of autologous T lymphocytes genetically modified to express a T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A2-restricted, melanoma-associated antigen C2 (MAGE-C2; MC2), ALK epitope, with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with an anti-MAGE-C2-HLA-A2 restricted TCR, expanded ex vivo, and reintroduced into the HLA-A2-positive patient. Upon reintroduction, the autologous MAGE-C2-specific HLA-A2-restricted TCR T lymphocytes bind to tumor cells expressing the MAGE-C2 antigen, which may induce cell death in and halt the growth of MAGE-C2-expressing cancer cells. MAGE-C2, a cancer/testis tumor-associated antigen (CT-TAA), is overexpressed by a variety of cancer cell types.